Drug manufacturers and other trade industry experts have warned that the new proposal could actually raise drug prices. (Photo: Shutterstock)
Reining in the high cost of prescription drugs has been a major aim of the Trump administration, marked most notably by the president's 2018 "Blueprint to Lower Drug Prices" directive. Since then, the administration has rolled out numerous orders and regulations aimed at bringing reform to the pharmaceutical industry–only to be met with resistance at nearly every turn.
Though many of those initiatives have been slow to get started or stalled by legal challenges, a new executive order from President Trump requiring the government to buy certain drugs from American factories could have some teeth. As reported by Stat News, as much as 90% of the country's supply of generic drugs is manufactured abroad.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Emily Payne
Emily Payne is director, content analytics for ALM's Business & Finance Markets and former managing editor for BenefitsPRO. A Wisconsin native, she has spent the past decade writing and editing for various athletic and fitness publications. She holds an English degree and Business certificate from the University of Wisconsin.
